Treatments

PD-1 vs PD-L1 in Cancer Records: Why Translation Accuracy Matters Before Care in China

Learn why PD-1 and PD-L1 terminology, biomarker reports, scoring methods and translation accuracy matter for international cancer patients preparing records before care in China.

MedToChina Editorial Team · 8 min read · September 2, 2026

PD-1 vs PD-L1 in Cancer Records: Why Translation Accuracy Matters Before Care in China

Quick Summary

PD-1 and PD-L1 are connected but different terms; confusing them can make oncology records harder to use.
PD-L1 test reports may include score type, clone, assay, specimen site and cancer-specific interpretation details.
A PD-L1 result does not by itself decide whether immunotherapy is appropriate.
International patients should send original reports plus translations, not simplified summaries alone.
MedToChina can receive records through WhatsApp and discuss what information may still be needed for China care communication.

International patients searching for PD-1 vs PD-L1 are often trying to understand whether an immunotherapy record, pathology result or biomarker report may affect care planning in China. This guide explains the terminology in patient-friendly language and focuses on record preparation, translation accuracy and safe communication. It does not provide a diagnosis or choose a treatment.

Why PD-1 and PD-L1 confusion is common

Cancer patients often see PD-1, PD-L1, immunotherapy, checkpoint inhibitor, pembrolizumab, nivolumab, atezolizumab or durvalumab in different reports. These words can appear in pathology records, drug lists, clinical notes, biomarker panels and treatment summaries. It is easy for patients and families to treat them as one general concept: immunotherapy. For practical care planning, however, the exact wording matters.

PD-1 and PD-L1 are part of the same immune checkpoint pathway, but they describe different biological parts. PD-1 is generally discussed as a protein on T cells. PD-L1 may be expressed on some tumor cells and other cells. Drugs may target PD-1 or PD-L1, while tests often measure PD-L1 expression in tumor tissue. If a translation turns a PD-L1 test into a PD-1 test, or describes a PD-1 drug as a PD-L1 result, the record package becomes less reliable.

PD-1 vs PD-L1 in plain language

A simple way to understand the pathway is to think of immune checkpoints as signals that help control immune attack. The National Cancer Institute explains that checkpoint proteins can keep immune responses in check, and that blocking the PD-1 and PD-L1 interaction can allow T cells to attack cancer cells in some treatment contexts. This is why drugs called immune checkpoint inhibitors are used in several cancer types.

For patients, the key point is not to memorize immunology. The key point is to separate three things: the pathway, the drug target and the test result. PD-1 may refer to the target of a drug. PD-L1 may refer to a protein measured by an immunohistochemistry test. A treatment note may say the patient received an anti-PD-1 agent, while a pathology report may say PD-L1 TPS 50 percent or CPS 10. Those statements mean different things.

Where these terms appear in cancer records

PD-1 and PD-L1 terminology can appear in pathology reports, molecular tumor board notes, oncology clinic summaries, discharge papers, medication lists, clinical trial eligibility notes and insurance documents. A pathology report may describe PD-L1 immunohistochemistry and a scoring method. A medication list may describe prior exposure to a PD-1 inhibitor. A clinical note may say progression after immunotherapy. These details help clinicians understand what was tested and what was already tried.

International patients considering care in China should not send only a short summary such as 'PD positive' or 'immunotherapy failed.' The record package should show the cancer type, specimen site, test date, scoring method, score, drug names, treatment dates, response, side effects and current disease status. If possible, include the original pathology report, translated summary and recent imaging.

PD-L1 testing: score, clone and cancer type

A PD-L1 report may include terms such as TPS, CPS, immune-cell score, tumor-cell score, staining intensity, clone number and assay name. TPS and CPS are not interchangeable. Different cancer types and drug indications can use different scoring rules or thresholds. A result that is meaningful in non-small cell lung cancer may not be interpreted the same way in gastric cancer, cervical cancer, urothelial cancer or triple-negative breast cancer.

This is where translation errors can become operational problems. Translating CPS as a simple percentage, dropping the clone, omitting the specimen site, or leaving out whether the result came from a primary tumor or metastasis can reduce the value of the report. Patients do not need to interpret the test themselves, but they should protect the original details.

Drug target versus biomarker result

Another common confusion is mixing up a drug with a test. A record may say the patient received pembrolizumab or nivolumab, which are commonly described as PD-1 inhibitors. Another record may say PD-L1 expression was measured. These are related but not the same. A patient can have prior PD-1 treatment even if the PD-L1 report is negative, missing or not required for that specific context.

Likewise, a PD-L1 positive report does not automatically mean a patient should receive a particular drug in China. Cancer type, stage, prior therapies, organ function, autoimmune disease history, performance status, other biomarkers, current symptoms and regulatory or hospital pathways all matter. The report is one piece of the case, not the entire decision.

Why translation accuracy matters before care in China

International patient communication often crosses several language systems. A patient may have reports in English, Arabic, French, Thai, Vietnamese, Russian or another language, then need English or Chinese summaries for care planning in China. Oncology terms are compact and technical, so small errors can create large confusion. PD-1, PD-L1, PDL1, programmed death receptor, programmed death ligand, checkpoint inhibitor and immunotherapy should not be merged carelessly.

Before WhatsApp communication, patients should keep original documents and translations together. Label each file with date, hospital, specimen site and report type. If a translator is not familiar with oncology, ask them not to simplify technical fields. The goal is not beautiful prose. The goal is accurate transmission of drug names, biomarkers, scores, dates and treatment sequence.

What international patients should prepare

A strong oncology record package should include pathology, immunohistochemistry, PD-L1 report if available, NGS or molecular reports, staging information, imaging reports and DICOM files if available, treatment history, drug names, treatment dates, response, side effects, current medication list and recent blood tests. If the patient had immune-related side effects, such as colitis, hepatitis, pneumonitis, thyroiditis or diabetes, include those records clearly.

For patients exploring China care pathways, the question should be practical: what information would a qualified oncology team need to understand the case? If prior immunotherapy was stopped because of progression, toxicity, cost, access, infection or patient choice, say so. If the patient is currently on steroids or immunosuppressive medication, include the name and dose.

Questions to ask before traveling to China

Patients can prepare focused questions: Was my PD-L1 test performed on the most relevant tissue sample? Does the report show TPS, CPS or another score? Is the assay clone listed? Which PD-1 or PD-L1 drugs have I already received? Did I stop because of progression or side effects? Are other biomarkers such as EGFR, ALK, ROS1, BRAF, MSI, TMB, HER2, NTRK or CLDN18.2 relevant to my cancer type?

These questions do not replace medical evaluation, but they make the first communication more efficient. They also reduce the chance that a patient travels with a record package that looks large but lacks the specific information needed for oncology planning.

Side effects and safety history should not be hidden

Immune checkpoint inhibitors can cause immune-related side effects because they change how immune responses are controlled. Medical sources commonly discuss inflammation of organs such as the lung, colon, liver, endocrine glands, skin and other systems. A patient who previously had severe immune-related toxicity should make that history visible in the record package.

Some patients worry that reporting side effects will reduce treatment options. In reality, hiding serious toxicity can make planning less safe. China care communication should start from accurate history, not selective history. If you had hospitalization, high-dose steroids, treatment interruption or long-term hormone replacement after immunotherapy, include those records.

How MedToChina supports WhatsApp record communication

MedToChina can receive your oncology records, translated summaries and questions through WhatsApp. After understanding your cancer type, treatment history, biomarker reports, country of residence, travel window, budget range and available documents, the customer service team can discuss what information may still be needed for possible care communication in China.

The website does not interpret PD-L1 scores as a diagnosis, choose a drug, confirm trial eligibility or promise treatment access. Its role is to help international patients organize the right information and understand what questions to prepare before China-side medical communication continues.

Why international patients may consider care in China

China has oncology, pathology, imaging and advanced treatment resources in major cities such as Beijing, Shanghai and Guangzhou. For some overseas patients, China may be relevant when they need organized review of prior records, biomarker-driven treatment pathway discussion, access to oncology resources, or a second planning route after standard options become limited in their home system.

The practical first step is still record preparation. China-side communication works better when reports are complete, translated accurately and organized by date. A patient with clear pathology, PD-L1 report, molecular testing, prior treatment history and recent imaging can have a more focused planning conversation than a patient who sends only screenshots and partial translations.

What to send before WhatsApp communication

Original pathology report and translated version if available.
PD-L1 report showing score type, score, assay or clone, specimen site and date if listed.
Immunotherapy drug history, including drug names, dates, response and side effects.
NGS or molecular reports, especially if they include driver mutations or resistance findings.
Recent imaging reports and DICOM files when available.
Current medication list, steroid use, autoimmune history and immune-related adverse event history.
Country of residence, preferred travel window, language needs and the questions you want answered.

FAQ

Are PD-1 and PD-L1 the same thing?

No. PD-1 is a checkpoint protein found on immune cells such as T cells, while PD-L1 is a ligand that can be found on some normal cells and cancer cells. They are connected in the same pathway, but they are not the same term in a medical record.

Why does the wording matter in my cancer report?

A report may describe a drug target, a test result, a tumor biomarker, a staining clone, a score, or a treatment already received. Translating these as if they were the same can confuse the care-planning conversation.

Does a positive PD-L1 test mean immunotherapy will work?

Not by itself. PD-L1 may help guide treatment in some cancers, but decisions can also depend on cancer type, stage, prior treatment, performance status, other biomarkers, guideline context and medical judgment.

Should I send the original pathology report or only a translation?

Send both when possible. The original report preserves details such as clone, TPS, CPS, percentage, specimen site and date, while the translation helps communication.

Can MedToChina decide whether I need a PD-1 or PD-L1 drug?

No. MedToChina can help organize records and WhatsApp communication. Treatment decisions require qualified oncology evaluation based on the full case.

Related MedToChina Resources

WhatsApp CTA

Send your pathology report, PD-L1 report if available, immunotherapy treatment history, molecular testing, recent scans and main questions through WhatsApp. MedToChina’s customer service team can discuss what information may still be needed before possible oncology care communication in China.

Medical Disclaimer

This article is for general health information and international patient planning only. It does not provide a diagnosis, prescribe treatment, confirm eligibility, confirm access to a hospital or doctor, or replace an in-person evaluation by qualified medical professionals. Cancer treatment decisions require licensed oncology evaluation based on the full medical record, current condition, local regulations and patient-specific risk.